Ascentage Pharma Group International (NASDAQ:AAPG) versus Avid Bioservices (NASDAQ:CDMO) Critical Survey

Ascentage Pharma Group International (NASDAQ:AAPG) and Avid Bioservices (NASDAQ:CDMO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.

Profitability

This table compares Ascentage Pharma Group International and Avid Bioservices’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Avid Bioservices	-101.07%	-33.18%	-8.45%

Valuation and Earnings

This table compares Ascentage Pharma Group International and Avid Bioservices”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
Avid Bioservices	$139.91 million	5.71	-$140.75 million	($2.39)	-5.23

Ascentage Pharma Group International has higher earnings, but lower revenue than Avid Bioservices.

Insider & Institutional Ownership

97.2% of Avid Bioservices shares are held by institutional investors. 3.1% of Avid Bioservices shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for Ascentage Pharma Group International and Avid Bioservices, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0	0	0	0	0.00
Avid Bioservices	0	4	0	0	2.00

Avid Bioservices has a consensus price target of $12.25, suggesting a potential downside of 1.96%. Given Avid Bioservices’ stronger consensus rating and higher probable upside, analysts plainly believe Avid Bioservices is more favorable than Ascentage Pharma Group International.

Summary

Avid Bioservices beats Ascentage Pharma Group International on 5 of the 8 factors compared between the two stocks.

About Ascentage Pharma Group International

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

About Avid Bioservices

Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.